Q1 EPS Forecast for Voyager Therapeutics Boosted by Analyst

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Voyager Therapeutics in a note issued to investors on Thursday, March 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.21) per share for the quarter, up from their previous estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.47) EPS and FY2029 earnings at ($1.40) EPS.

Several other research analysts also recently commented on VYGR. Canaccord Genuity Group lowered their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Citigroup began coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Finally, Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Trading Down 0.3 %

Shares of VYGR stock opened at $3.88 on Monday. Voyager Therapeutics has a 1 year low of $3.56 and a 1 year high of $10.66. The stock has a market cap of $214.20 million, a P/E ratio of 5.46 and a beta of 0.99. The stock has a 50 day simple moving average of $4.75 and a 200 day simple moving average of $5.78.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the firm posted $1.25 earnings per share.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 10,778 shares of company stock worth $58,548. Corporate insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics during the fourth quarter valued at $29,000. Tower Research Capital LLC TRC boosted its position in Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after acquiring an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management boosted its position in Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after acquiring an additional 2,444 shares during the last quarter. Oxford Asset Management LLP bought a new stake in Voyager Therapeutics during the fourth quarter valued at $60,000. Finally, Intech Investment Management LLC bought a new stake in Voyager Therapeutics during the third quarter valued at $74,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.